Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Defy Medical vs Omada Health

Defy Medical
Graded #325

Higher grade

vs+4.600000000000001
Omada Health
Graded #435

Lower grade

The verdict

Defy Medical takes it — 60.2/100 to 55.6/100.

Defy Medical grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Defy Medical is a long-running telehealth clinic, best known for hormone replacement, that also prescribes GLP-1 medications for weight loss.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEven
45
45
Dose & formulationDefy Medical +16
56
40
Clinical oversightDefy Medical +3
80
77
Labs & monitoringDefy Medical +4
65
61
FulfillmentDefy Medical +1
63
62
Contract termsEven
55
55
Defy Medical · left barOmada Health · right bar

The numbers

MetricDefy MedicalOmada Health
WeighScore60.2/10055.6/100
GradeCC
Scorecard rank#325#435
SemaglutideNot disclosedNot disclosed
TirzepatideNot disclosedNot disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
Defy Medical

Graded #325 · C

Strengths

  • Multiple GLP-1 options: semaglutide, tirzepatide, liraglutide
  • Offers injection, ODT, and oral drop delivery forms
  • Comprehensive blood testing and named medical director
  • Established clinic with strong Trustpilot review volume

Where it loses points

  • GLP-1 pricing not published on the website
  • States served and shipping limits not disclosed
  • Compounded versus brand status not stated online
  • Lab-heavy, consult-first model may cost more upfront
Omada Health

Graded #435 · C

Strengths

  • Added GLP-1 prescribing and medication management in late 2025
  • Clinicians trained in obesity care, available in all 50 states
  • Behavioral support wrapped before, during and after treatment
  • GLP-1 Flex Care adds a cash-pay medication pathway in 2026
  • Publicly traded, evidence-based virtual care platform

Where it loses points

  • Core program distributed via employers and health plans, limited cash-pay
  • GLP-1 prescribing is a recent addition still scaling
  • GLP-1 Flex Care only rolling out to employers later in 2026
  • No transparent published price for the core member program

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard